The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Ralph R. Weichselbaum and Philip P. Connell.
Connection Strength

2.630
  1. Small molecule derived from a natural product that mitigates radiation injury. Proc Natl Acad Sci U S A. 2013 Nov 12; 110(46):18355-6.
    View in: PubMed
    Score: 0.479
  2. A downside to apoptosis in cancer therapy? Nat Med. 2011 Jul 07; 17(7):780-2.
    View in: PubMed
    Score: 0.408
  3. Relevance and irrelevance of DNA damage response to radiotherapy. DNA Repair (Amst). 2004 Aug-Sep; 3(8-9):1245-51.
    View in: PubMed
    Score: 0.252
  4. Gene therapy: the challenges of translating laboratory research into clinical practice. J Clin Oncol. 2003 Jun 15; 21(12):2230-1.
    View in: PubMed
    Score: 0.233
  5. Retuning the Radio in Radiobiology. J Natl Cancer Inst. 2018 04 01; 110(4):325-326.
    View in: PubMed
    Score: 0.163
  6. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4493-4500.
    View in: PubMed
    Score: 0.151
  7. The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors. Cancer Res. 2014 Jul 01; 74(13):3546-55.
    View in: PubMed
    Score: 0.124
  8. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42.
    View in: PubMed
    Score: 0.123
  9. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013 Feb 20; 5(173):173sr2.
    View in: PubMed
    Score: 0.114
  10. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
    View in: PubMed
    Score: 0.104
  11. A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci U S A. 2008 Oct 14; 105(41):15848-53.
    View in: PubMed
    Score: 0.084
  12. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9.
    View in: PubMed
    Score: 0.071
  13. A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin. Cancer Res. 2004 May 01; 64(9):3002-5.
    View in: PubMed
    Score: 0.062
  14. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. NPJ Precis Oncol. 2022 Oct 14; 6(1):72.
    View in: PubMed
    Score: 0.056
  15. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.052
  16. Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001 Jan 01; 19(1):54-61.
    View in: PubMed
    Score: 0.049
  17. Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results. Urology. 1999 Nov; 54(5):875-9.
    View in: PubMed
    Score: 0.045
  18. RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells. Nucleic Acids Res. 2015 Mar 31; 43(6):3180-96.
    View in: PubMed
    Score: 0.033
  19. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.